A Wearable Microfluidic Sweat‐Patch Pilot Study for Detecting Breast‐Cancer Proteins CEA and PIP/GCDFP‐15
Advanced Healthcare Materials · 13.11.2026
DOI: 10.1002/adhm.71983 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 13.11.2026. Verfasst von Fatemeh Esmaeildoost und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Advanced Biotechnologies for Health Assessments (Lab-HA), Lassonde School of Engineering, York University, Toronto, Ontario, Canada. Die Arbeit nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: York University, Natural Sciences and Engineering Research Council of Canada, Ontario Centre of Innovation.
Abstract (Originalsprache)
Blood‐based measurement of carcinoembryonic antigen (CEA) and gross cystic disease fluid protein‐15 (GCDFP‐15; prolactin‐inducible protein, PIP) remains the standard for breast cancer monitoring but is invasive. We present WearDOXXN + , a capillary‐driven microfluidic patch for noninvasive sweat collection to investigate paired sweat–blood analysis. Ten participants wear the patch during exercise; matched sweat and blood samples are analyzed by enzyme‐linked immunosorbent assay (ELISA). The platform collects sweat within 30 min, with 100% success. CEA was detected in sweat and showed a disease‐stage‐associated trend; however, concentrations in healthy participants and survivors remained below the assay's lower limit of quantification, highlighting analytical sensitivity as a limitation. PIP was measurable in blood, with the highest level observed in Stage III disease, although several values exceeded the assay's validated upper limit, while remaining undetectable in sweat. Validation showed the patch recovers 65% of loaded fluid, and recovered eluate retains loaded CEA concentration (recovery 108%, 92%, and 98%), confirming sample handling does not deplete the analyte. These findings represent, to our knowledge, the first paired sweat–blood comparison of CEA and PIP using a passive capillary‐driven wearable patch and establish analytical requirements, including sample volume, analyte recovery, assay sensitivity, and biomarker selection, for noninvasive sweat‐based breast cancer monitoring.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Laboratory of Advanced Biotechnologies for Health Assessments (Lab-HA), Lassonde School of Engineering, York University, Toronto, Ontario, Canada.
- Department of Mechanical Engineering, Lassonde School of Engineering, York University, Toronto, Ontario, Canada.
- Department of Electrical Engineering and Computer Science, Lassonde School of Engineering, York University, Toronto, Ontario, Canada.
- Department of Biology, Faculty of Science, York University, Toronto, Ontario, Canada.
ORCID-Profile: Fatemeh Esmaeildoost, Siu Ning Leung, Razieh Salahandish
Förderung
- York University
- Natural Sciences and Engineering Research Council of Canada
- Ontario Centre of Innovation
- Mitacs Business Strategy Internship
- Mitacs Accelerate Awards
Zitieren
APA
Esmaeildoost, F., Arshadi, S., Rahimi, F., Najafpour, M., Chian, M. F., Sachlos, E., Leung, S. N., & Salahandish, R. (2026). A Wearable Microfluidic Sweat‐Patch Pilot Study for Detecting Breast‐Cancer Proteins CEA and PIP/GCDFP‐15. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.71983
Vancouver
Esmaeildoost F, Arshadi S, Rahimi F, Najafpour M, Chian MF, Sachlos E, et al. A Wearable Microfluidic Sweat‐Patch Pilot Study for Detecting Breast‐Cancer Proteins CEA and PIP/GCDFP‐15. Advanced Healthcare Materials. 2026. doi:10.1002/adhm.71983
BibTeX
@article{Esmaeildoost2026,
author = {Esmaeildoost, Fatemeh and Arshadi, Soroosh and Rahimi, Fatemeh and Najafpour, Mehrdad and Chian, Milad Falahat and Sachlos, Eleftherios and Leung, Siu Ning and Salahandish, Razieh},
title = {A Wearable Microfluidic Sweat‐Patch Pilot Study for Detecting Breast‐Cancer Proteins CEA and PIP/GCDFP‐15},
journal = {Advanced Healthcare Materials},
year = {2026},
doi = {10.1002/adhm.71983}
}
EUVIMED